{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:05:14Z","timestamp":1794434714096,"version":"4.9.1"},"reference-count":59,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,9,29]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare international substandard and falsified (SF) medicine recall trends from published research papers based on governmental databases, summarise the extent of the problem in the legitimate supply chain, and identify ways to manage the issue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review of published academic evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Drug recall data in published literature, obtained from official international government regulator databases in the USA, the UK, Canada, Sri Lanka, Zambia, Portugal, Nepal, Saudi Arabia, Argentina, Brazil, Chile, Cuba, Colombia, Mexico, Bolivia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Panama, Peru and Venezuela.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>A search for literature published between 2010 and 2024 was conducted using PubMed, MEDLINE and Embase. Included studies examined recall data of substandard and\/or falsified medicines obtained through official government regulator websites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>Data were extracted using Excel files and synthesised using a thematic analysis approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>13 research papers containing original data were included. Recall data were obtained from official regulatory databases in 23 different countries. Substandard medicines had significantly higher recall rates than falsified products, while parenteral drugs and tablets were the most recalled formulation types. The leading reasons for defective medicines were contamination, out-of-specification results, stability and packaging issues. India was identified as a common source of SF medicines in Zambia, Sri Lanka, Brazil and Nepal. Frequent recalls of anti-infective drugs were observed in countries with equatorial, tropical and subtropical climates, while high-income countries like Canada, Saudi Arabia and the UK faced issues with defective antihypertensive drugs. Interestingly, medicines affected by nitrosamines\u2019 contamination were recalled in all regions examined in 2018, but in other recall cases, there were disparities among recall action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There appeared to be similar international recall practices for some products like nitrosamines and not for others like rosiglitazone across the same time frame, which raises questions concerning international drug safety disparities. The requirement to align and globally strengthen regulatory frameworks was of emerging importance. Cooperation between regulatory authorities to create a harmonised approach to reporting medicine recalls and standardising the data included in a recall notification is proposed to facilitate a more accurate comparison of international trends surrounding recalled SF medicines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-103672","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T02:10:26Z","timestamp":1761617426000},"page":"e103672","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Substandard and falsified medicine recalls in the legitimate supply chain: a systematic review of evidence"],"prefix":"10.1136","volume":"15","author":[{"given":"Izabella","family":"Fryze","sequence":"first","affiliation":[{"name":"The School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6947-8297","authenticated-orcid":false,"given":"Bernard D","family":"Naughton","sequence":"additional","affiliation":[{"name":"The School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland"},{"name":"The Centre for Pharmaceutical Medicine Research, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"2025120415083808000_15.10.e103672.1","unstructured":"Falsified medicines: overview (no date). European Medicines Agency (EMA). Available: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/public-health-threats\/falsified-medicines-overview#:~:text=Falsified%20medicines%20are%20fake%20medicines%20that%20are%20designed%20to%20mimic,or%20that%20infringe%20trademark%20law [Accessed 10 Sep 2024]."},{"key":"2025120415083808000_15.10.e103672.2","unstructured":"1 in 10 medical products in developing countries is substandard or falsified (no date). World Health Organization. Available: https:\/\/www.who.int\/news\/item\/28-11-2017-1-in-10-medical-products-in-developing-countries-is-substandard-or-falsified [Accessed 10 Sep 2024]."},{"key":"2025120415083808000_15.10.e103672.3","unstructured":"Substandard and falsified medical products. World Health Organization; 2018. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/substandard-and-falsified-medical-products [Accessed 30 Sep 2024]."},{"key":"2025120415083808000_15.10.e103672.4","unstructured":"Medical product alert n\u00b02\/2024: falsified ozempic (semaglutide). 2024 Available: https:\/\/www.who.int\/news\/item\/19-06-2024-medical-product-alert-n-2-2024--falsified-ozempic-(semaglutide)"},{"key":"2025120415083808000_15.10.e103672.5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1741134316643358","article-title":"EU Falsified Medicines Directive mandatory requirements for secondary care: A concise review","volume":"12","author":"Naughton","year":"2015","journal-title":"J Generic Med"},{"key":"2025120415083808000_15.10.e103672.6","unstructured":"Naughton BD . The eu falsified medicines directive: key implications for dispensers. med access @ point care. 2017. Available: http:\/\/medicine-access.pointofcarejournals.com\/article\/f44f56ed-a619-4935-8c49-b7524265a973?permalink=f44f56ed-a619-4935-8c49-b7524265a973"},{"key":"2025120415083808000_15.10.e103672.7","unstructured":"Falsified medicines legislation. Available: http:\/\/www.hpra.ie\/homepage\/medicines\/special-topics\/falsified-medicines-legislation [Accessed 15 Sep 2024]."},{"key":"2025120415083808000_15.10.e103672.8","unstructured":"Who urges action to protect children from contaminated medicines (no date). World Health Organization. Available: https:\/\/www.who.int\/news\/item\/23-01-2023-who-urges-action-to-protect-children-from-contaminated-medicines [Accessed 10 Sep 2024]."},{"key":"2025120415083808000_15.10.e103672.9","doi-asserted-by":"crossref","unstructured":"Naughton BD , Akgul E . Medicine quality in high-income countries: The obstacles to comparative prevalence studies. Med Access Point Care 2021;5. doi:10.1177\/23992026211052272","DOI":"10.1177\/23992026211052272"},{"key":"2025120415083808000_15.10.e103672.10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-002393","article-title":"A systematic review of substandard, falsified, unlicensed and unregistered medicine sampling studies: a focus on context, prevalence, and quality","volume":"5","author":"McManus","year":"2020","journal-title":"BMJ Glob Health"},{"key":"2025120415083808000_15.10.e103672.11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.1662","article-title":"Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis","volume":"1","author":"Ozawa","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2025120415083808000_15.10.e103672.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002924","article-title":"Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001-2011)","volume":"3","author":"Almuzaini","year":"2013","journal-title":"BMJ Open"},{"key":"2025120415083808000_15.10.e103672.13","doi-asserted-by":"crossref","unstructured":"AlQuadeib BT , Alfagih IM , Alnahdi AH , et al . Medicine recalls in Saudi Arabia: a retrospective review of drug alerts (January 2010\u2013January 2019). Futur J Pharm Sci 2020;6. doi:10.1186\/s43094-020-00112-3","DOI":"10.1186\/s43094-020-00112-3"},{"key":"2025120415083808000_15.10.e103672.14","doi-asserted-by":"crossref","unstructured":"Chabalenge B , Jere E , Nanyangwe N , et al . Substandard and falsified medical product recalls in Zambia from 2018 to 2021 and implications on the quality surveillance systems. J Med Access 2022;6. doi:10.1177\/27550834221141767","DOI":"10.1177\/27550834221141767"},{"key":"2025120415083808000_15.10.e103672.15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-053479","article-title":"Review of drug recalls and quality of pharmaceutical products in Nepal","volume":"12","author":"Neupane","year":"2022","journal-title":"BMJ Open"},{"key":"2025120415083808000_15.10.e103672.16","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-020-01726-9","article-title":"An Analytic Investigation of the Drug Formulation-Based Recalls in the USA: See More Beyond the Literal","volume":"21","author":"Yang","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"2025120415083808000_15.10.e103672.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-023-09225-w","article-title":"Recall of substandard medicines in Brazil during the period 2010-2018","volume":"23","author":"Oliveira","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"2025120415083808000_15.10.e103672.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-023-09995-3","article-title":"Quality of medicines in Sri Lanka: a retrospective review of safety alerts","volume":"23","author":"Tharmalinga Sharma","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"2025120415083808000_15.10.e103672.19","doi-asserted-by":"crossref","DOI":"10.4322\/2179-443X.0753","article-title":"Reports of substandard medicines: a lexicographic analysis of the Brazilian Health Surveillance Report System","volume":"42","author":"Fedalto","year":"2021","journal-title":"Rev Ci\u00eanc Farm B\u00e1sica Apl"},{"key":"2025120415083808000_15.10.e103672.20","unstructured":"Open Resources for Nursing (Open RN) . Chapter 18 administration of parenteral medications. In: Ernstmeyer K , Christman E , eds. Nursing skills. Eau Claire (WI): Chippewa Valley Technical College, 2021. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK593214\/"},{"key":"2025120415083808000_15.10.e103672.21","unstructured":"Pharmaceutical market size to hit around usd 2,832.66 bn by 2033. BioSpace; 2024. Available: https:\/\/www.biospace.com\/pharmaceutical-market-size-to-hit-around-usd-2-832-66-bn-by-2033 [Accessed 3 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.22","unstructured":"Formulation and manufacturing trends for parenterals. PharmTech; 2019. Available: https:\/\/www.pharmtech.com\/view\/formulation-and-manufacturing-trends-parenterals [Accessed 2 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.23","unstructured":"World bank country and lending groups (no date) world bank country and lending groups \u2013 world bank data help desk. Available: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups [Accessed 2 Sep 2024]."},{"key":"2025120415083808000_15.10.e103672.24","unstructured":"World bank climate change knowledge portal (no date) climatology. Climate Change Knowledge Portal. Available: https:\/\/climateknowledgeportal.worldbank.org\/country\/sri-lanka\/climate-data-historical [Accessed 2 Sep 2024]."},{"key":"2025120415083808000_15.10.e103672.25","unstructured":"World bank climate change knowledge portal (no date) climatology. Climate Change Knowledge Portal. Available: https:\/\/climateknowledgeportal.worldbank.org\/country\/brazil\/climate-data-historical#:~:text=Brazil%20experiences%20equatorial%2C%20tropical%20as,to%20the%20planet%27s%20energy%20balance [Accessed 2 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.26","unstructured":"World bank country classifications by income level for 2024-2025 (no date). World Bank Blogs. Available: https:\/\/blogs.worldbank.org\/en\/opendata\/world-bank-country-classifications-by-income-level-for-2024-2025 [Accessed 2 Sep 2024]."},{"key":"2025120415083808000_15.10.e103672.27","unstructured":"Christian M , et al . Geographic concentration of pharmaceutical manufacturing: usp medicine supply map analysis, geographic concentration of pharmaceutical manufacturing: usp medicine supply map analysis. Quality Matters | U.S. Pharmacopeia Blog; 2022. Available: https:\/\/qualitymatters.usp.org\/geographic-concentration-pharmaceutical-manufacturing [Accessed 2 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.28","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/bmj.p785","article-title":"Indian government cracks down on 18 drug companies for poor quality manufacturing","volume":"381","author":"Thiagarajan","year":"2023","journal-title":"BMJ"},{"key":"2025120415083808000_15.10.e103672.29","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1136\/bmj.p2951","article-title":"India\u2019s medicine regulator is criticised for quality checking only cough medicines destined for export","volume":"383","author":"Thiagarajan","year":"2023","journal-title":"BMJ"},{"key":"2025120415083808000_15.10.e103672.30","unstructured":"Team E . Indian pharma companies under investigation for poor drug quality donate millions to political parties. Health Policy Watch; 2024. Available: https:\/\/healthpolicy-watch.news\/indian-pharma-companies-under-investigation-for-poor-drug-quality-donate-millions-to-political-parties\/ [Accessed 3 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.31","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.31729\/jnma.7684","article-title":"Counterfeit Healthcare Products: Nepal at a Vulnerable Position","volume":"60","author":"Bhandari","year":"2022","journal-title":"J Nepal Med Assoc"},{"key":"2025120415083808000_15.10.e103672.32","unstructured":"TNN . Fake antibiotics worth rs 51 lakh seized. Ahmedabad News - Times of India; 2016. Available: https:\/\/timesofindia.indiatimes.com\/city\/ahmedabad\/fake-antibiotics-worth-rs-51l-seized\/articleshow\/56092039.cms [Accessed 10 Sep 2024]."},{"key":"2025120415083808000_15.10.e103672.33","unstructured":"Embassy of India Riyadh, Saudi Arabia (no date) Embassy of India, Riyadh, Saudi Arabia . India-Saudi bilateral relations. Available: https:\/\/www.eoiriyadh.gov.in\/page\/india-saudi-bilateral-relations\/#:~:text=Our%20trade%20relationship%20has%20been,amounted%20to%20USD%2031.8%20billion [Accessed 5 Sep 2024]."},{"key":"2025120415083808000_15.10.e103672.34","unstructured":"NHS choices. 2022. Available: https:\/\/www.nhs.uk\/medicines\/valsartan\/about-valsartan\/ [Accessed 3 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.35","unstructured":"Update on review of recalled valsartan medicines: preliminary assessment of possible risk to patients. European Medicines Agency (EMA); 2018. Available: https:\/\/www.ema.europa.eu\/en\/news\/update-review-recalled-valsartan-medicines-preliminary-assessment-possible-risk-patients [Accessed 3 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.36","unstructured":"Berthold J . Fentanyl pain-relief patches recalled for packaging defect. I.M. Matters from ACP; 2008. Available: https:\/\/immattersacp.org\/archives\/2008\/04\/twentytwo.htm [Accessed 20 Sep 2024]."},{"key":"2025120415083808000_15.10.e103672.37","doi-asserted-by":"publisher","DOI":"10.5731\/pdajpst.2017.007567"},{"key":"2025120415083808000_15.10.e103672.38","unstructured":"Center for Drug Evaluation and Research . Pat - a framework for innovative pharmaceutical development, manufacturing, and quality assurance. U.S. Food and Drug Administration; 2018. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pat-framework-innovative-pharmaceutical-development-manufacturing-and-quality-assurance [Accessed 17 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.39","unstructured":"Process analytical technologies (pat) for packaging. European Pharmaceutical Review; 2014. Available: https:\/\/www.europeanpharmaceuticalreview.com\/article\/24951\/pat-packaging-review-applications-expeditious-nondestructive-quality-testing\/ [Accessed 17 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.40","unstructured":"Heatwaves, spread of infectious diseases due to climate change growing health threats to Europeans. European Environment Agency\u2019s home page; 2022. Available: https:\/\/www.eea.europa.eu\/en\/newsroom\/news\/heatwaves-spread-infectious-diseases [Accessed 1 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.41","unstructured":"Socioeconomic factors. Centers for Disease Control and Prevention; 2023. Available: https:\/\/www.cdc.gov\/dhdsp\/health_equity\/socioeconomic.htm#:~:text=Socioeconomic%20status%20is%20a%20multidimensional,from%20cardiovascular%20disease%20 [Accessed 1 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.42","unstructured":"UN list of least developed countries. United Nations Trade & Development; 2023. Available: https:\/\/unctad.org\/topic\/least-developed-countries\/list [Accessed 1 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.43","unstructured":"Economic Commission for Latin America and the Caribbean . Poverty rates in latin america remain above pre-pandemic levels in, comunicado poverty rates in Latin America remain above pre-pandemic levels in 2022, eclac warns. Economic Commission for Latin America and the Caribbean; 2022. Available: https:\/\/www.cepal.org\/en\/pressreleases\/poverty-rates-latin-america-remain-above-pre-pandemic-levels-2022-eclac-warns [Accessed 1 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.44","unstructured":"Sri lanka. ACAPS; 2024. Available: https:\/\/www.acaps.org\/en\/countries\/sri-lanka [Accessed 1 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.45","unstructured":"Dengue and severe dengue. World Health Organization. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue#:~:text=Overview,aches%2C%20nausea%2C%20and%20rash [Accessed 5 Sep 2024]."},{"key":"2025120415083808000_15.10.e103672.46","unstructured":"Suspected triple outbreak of typhoid fever, shigellosis and cholera. World Health Organization. Available: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2023-DON488 [Accessed 5 Sep 2024]."},{"key":"2025120415083808000_15.10.e103672.47","unstructured":"Hypertension. World Health Organization; 2023. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension [Accessed 4 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.48","unstructured":"World hypertension day: taking action against the silent epidemic of high blood pressure. World Heart Federation; 2022. Available: https:\/\/world-heart-federation.org\/news\/world-hypertension-day-taking-action-against-the-silent-epidemic-of-high-blood-pressure\/ [Accessed 4 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.49","unstructured":"Nepal. World Health Organization; 2024. Available: https:\/\/data.who.int\/countries\/524 [Accessed 5 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.50","unstructured":"United states of America. World Health Organization; 2024. Available: https:\/\/data.who.int\/countries\/840 [Accessed 5 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.51","unstructured":"Saudi Arabia regulatory system becomes third to reach who maturity level 4. World Health Organization. Available: https:\/\/www.who.int\/news\/item\/30-10-2023-saudi-arabia-regulatory-system-becomes-third-to-reach-who-maturity-level-4 [Accessed 10 Sep 2024]."},{"key":"2025120415083808000_15.10.e103672.52","unstructured":"FDA history. U.S. Food and Drug Administration. Available: https:\/\/www.fda.gov\/about-fda\/fda-history [Accessed 10 Sep 2024]."},{"key":"2025120415083808000_15.10.e103672.53","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.5.703"},{"key":"2025120415083808000_15.10.e103672.54","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.1685","article-title":"Prevalence of Substandard and Falsified Essential Medicines: Still an Incomplete Picture","volume":"1","author":"Mackey","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2025120415083808000_15.10.e103672.55","unstructured":"A study on the public health and socioeconomic impact of substandard and falsified medical products. World Health Organization; 2020. Available: https:\/\/www.who.int\/publications\/i\/item\/9789241513432 [Accessed 29 Jul 2025]."},{"key":"2025120415083808000_15.10.e103672.56","unstructured":"Center for Drug Evaluation and Research . FDA requires removal of some prescribing and dispensing restriction. U.S. Food and Drug Administration; 2018. Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-requires-removal-some-prescribing-and-dispensing-restrictions [Accessed 2 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.57","unstructured":"European medicines agency recommends suspension of avandia, avandamet and avaglim. European Medicines Agency (EMA); 2010. Available: https:\/\/www.ema.europa.eu\/en\/news\/european-medicines-agency-recommends-suspension-avandia-avandamet-avaglim [Accessed 2 Oct 2024]."},{"key":"2025120415083808000_15.10.e103672.58","doi-asserted-by":"crossref","unstructured":"OECD . OECD globalrecalls portal: 2015-2019 enhancements\u201d, oecd digital economy papers, no. 294. Paris OECD Publishing; 2020.294. Available: https:\/\/doi.org\/10.1787\/d8b0d605-en","DOI":"10.1787\/d8b0d605-en"},{"key":"2025120415083808000_15.10.e103672.59","unstructured":"Naughton B . The future of falsified and substandard medicine detection: digital methods to track and authenticate pharmaceutical products. Pathways for Prosperity Commission; 2018."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-103672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:15:22Z","timestamp":1764890122000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-103672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":59,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,27]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjopen-2025-103672"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-103672","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2025-103672.supp1","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2025-103672.supp2","asserted-by":"subject"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}